# OnCo record keynote-091 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-091/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-091", "NCT02504372" ;
  schema:name "KEYNOTE-091 (PEARLS)"@en ;
  schema:alternateName "PEARLS"@en, "EORTC-1416-LCG"@en, "ETOP 8-15"@en ;
  schema:description "Adjuvant pembrolizumab after lung cancer surgery delayed recurrence for everyone, but, unexpectedly, not for the group with the most PD-L1 on their tumour."@en ;
  schema:url <https://onco.cc/trials/keynote-091/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02504372>, <https://doi.org/10.1016/S1470-2045(22)00518-6>, <https://www.nice.org.uk/guidance/ta1037> ;
  onco:status "mixed" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/resectable-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-adjuvant/> ;
  onco:trials <https://onco.cc/trials/nct02486718/>, <https://onco.cc/trials/checkmate-816/>, <https://onco.cc/trials/keynote-671/> .